conatumumab
Conatumumab is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL receptor 2 with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin. — Wikipedia
Clinical trial activity
13 trials · 9 clinical orgs · 0 marketing orgs
Earliest trial started Jun 1, 2007 (NCT00630552)
Timeline
Indications
Studied for
- Carcinoid Tumor · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Hodgkin Disease · Phase 1
- Low Back Pain · Phase 1
- Lymphoma · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pain · Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Rectal Neoplasms · Phase 1/Phase 2
- Sarcoma · Phase 2
Mechanism of action
TNFRSF10B agonist
It binds to TNFRSF10B, activating intracellular caspases in vitro in the presence of a cross-linker.
TNFRSF10B inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaConatumumab ↗
- ChEMBLCHEMBL1743003 ↗
Also known as
- amg655
- amg 655
- amg 655
- amg 655
- amg-655
- amg-655
- amg-655
- azd1940
- azd1940
- azd1940
- conatumumab
- conatumumab
- conatumumab
- conatumumab
- conatumumab
- n-(2-tert-butyl-1-((4,4-difluorocyclohexyl)methyl)-1h-benzo(d)imidazol-5-yl)ethanesulfonamide
- trail-r2 mab
- xg1-048
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01940172 | Phase 1 | Nov 1, 2013 | TetraLogic Pharmaceuticals |
| NCT01327612 | Phase 2 | Mar 1, 2011 | Amgen |
| NCT01017822 | Phase 1/Phase 2 (Phase 2) | Nov 20, 2009 | National Cancer Institute (NCI), Radiation Therapy Oncology Group, University of Texas at Houston |
| NCT00813605 | Phase 2 | Mar 1, 2009 | Amgen, NantCell, Inc. |
| NCT00819169 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2009 | Amgen, NantCell, Inc. |
| NCT00689780 | Phase 1 | Mar 1, 2008 | AstraZeneca, IQVIA |
| NCT00659490 | Phase 2 | Feb 1, 2008 | AstraZeneca, Lifetree Clinical Research |
| NCT00791011 | Phase 1 | Feb 1, 2008 | Amgen |
| NCT00630786 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2008 | Amgen |
| NCT00534027 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2008 | Amgen |
| NCT00626704 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2007 | Amgen |
| NCT00625651 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2007 | Amgen |
| NCT00630552 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2007 | Amgen, NantCell, Inc. |
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 9 | 6 | 2 | 2007 |
| NantCell, Inc. | For profit | 3 | 3 | 1 | 2007 |
| AstraZeneca | For profit | 2 | 2 | 2 | 2008 |
| IQVIA | For profit | 1 | 0 | 1 | 2008 |
| Lifetree Clinical Research | For profit | 1 | 0 | 1 | 2008 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2009 |
| Radiation Therapy Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2009 |
| TetraLogic Pharmaceuticals | For profit | 1 | 1 | 1 | 2013 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2009 |